Previous 10 |
Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q4 GAAP EPS of -$0.86. More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Enrollment Completed in INVICTUS Pivotal Phase 3 Clinical Study in Fourth-line and Fourth-line Plus GIST; Top-line Data Expected in Mid-2019 - - INTRIGUE Pivotal Phase 3 Clinical Study Initiated in Second-line Patients with GIST - - Ended 2018 with Cash and Cash Equivalents of $...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen...
Current Deciphera Director and Experienced Commercial Oncology Executive, Steve Hoerter, Appointed as New President & Chief Executive Officer — Outgoing CEO Michael D. Taylor, Ph.D. to Continue to Serve as a Member of Board of Directors — Deciphera Pharmaceutica...
The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this Read more ...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 1 st Annual Guggenheim Healthcare T...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...